2 results match your criteria: "Osaka Prefectural Hospital Organization Osaka Japan.[Affiliation]"
Efficacy and safety of mycophenolate mofetil in treating immune-related hepatitis induced by immune checkpoint inhibitor use: A retrospective study.
JGH Open
February 2023
Department of Hepatobiliary and Pancreatic Oncology Osaka International Cancer Institute, Osaka Prefectural Hospital Organization Osaka Japan.
Background And Aim: To investigate the outcomes in eight Japanese patients with cancer treated with mycophenolate mofetil (MMF) and corticosteroids for immune checkpoint inhibitor treatment-induced severe immune-related hepatitis (ir-hepatitis) and the efficacy and safety of MMF.
Methods: We retrospectively examined patient background, treatment course, as well as examination and imaging data using electronic medical records.
Results: The ratio of male to female patients was 7:1, and the median age was 60 years (27-72 years).
A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer.
Ann Gastroenterol Surg
January 2023
Department of Gastroenterological Surgery, Graduate School of Medicine Osaka University Osaka Japan.
Purpose: Addition of perioperative multi-agent chemotherapy to the treatment strategy for locally advanced rectal cancer (LARC) may be a promising option. We conducted a phase II study to evaluate the safety and efficacy of capecitabine combined with oxaliplatin and irinotecan (XELOXIRI) as triplet neoadjuvant chemotherapy in patients with LARC.
Methods: Patients received neoadjuvant irinotecan and oxaliplatin and capecitabine and then underwent total mesorectal excision.